USD
$0.00
(0.00%
)At Close (As of Nov 4, 2025)
$26.78M
Market Cap
-
P/E Ratio
-0.4
EPS
$1.49
52 Week High
$0.62
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $3.7M |
| Total Revenue | $3.7M |
| Cost Of Revenue | $0 |
| Costof Goods And Services Sold | $0 |
| Operating Income | -$37M |
| Selling General And Administrative | $14M |
| Research And Development | $26M |
| Operating Expenses | $41M |
| Investment Income Net | - |
| Net Interest Income | $1.7M |
| Interest Income | $4.3M |
| Interest Expense | $2.6M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.7M |
| Income Before Tax | -$21M |
| Income Tax Expense | $151K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$21M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$20M |
| Ebitda | -$19M |
| Net Income | -$21M |
| Field | Value (USD) |
|---|---|
| Total Assets | $91M |
| Total Current Assets | $72M |
| Cash And Cash Equivalents At Carrying Value | $16M |
| Cash And Short Term Investments | $16M |
| Inventory | - |
| Current Net Receivables | $10M |
| Total Non Current Assets | $18M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $16M |
| Short Term Investments | $43M |
| Other Current Assets | $2.6M |
| Other Non Current Assets | - |
| Total Liabilities | $36M |
| Total Current Liabilities | $24M |
| Current Accounts Payable | $4.6M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $15M |
| Total Non Current Liabilities | $11M |
| Capital Lease Obligations | $2.6M |
| Long Term Debt | - |
| Current Long Term Debt | $14M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $16M |
| Other Current Liabilities | $3.4M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $55M |
| Treasury Stock | - |
| Retained Earnings | -$377M |
| Common Stock | $41K |
| Common Stock Shares Outstanding | $49M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$24M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.7M |
| Capital Expenditures | $0 |
| Change In Receivables | - |
| Change In Inventory | $0 |
| Profit Loss | - |
| Cashflow From Investment | $6.2M |
| Cashflow From Financing | -$139K |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$21M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $3.7M |
| Total Revenue | $3.7M |
| Cost Of Revenue | $0 |
| Costof Goods And Services Sold | $0 |
| Operating Income | -$37M |
| Selling General And Administrative | $14M |
| Research And Development | $26M |
| Operating Expenses | $41M |
| Investment Income Net | - |
| Net Interest Income | $1.7M |
| Interest Income | $4.3M |
| Interest Expense | $2.6M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.7M |
| Income Before Tax | -$21M |
| Income Tax Expense | $151K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$21M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$20M |
| Ebitda | -$19M |
| Net Income | -$21M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Scynexis Inc. is a biotechnology firm headquartered in Jersey City, New Jersey, specializing in innovative therapies for the treatment of invasive fungal infections, with a particular focus on serious yeast infections. The company’s lead product candidate, BREXAFEMME®, is the first oral therapeutic specifically indicated for the treatment of vulvovaginal candidiasis, representing a significant advancement in antifungal therapy. With a robust pipeline and a commitment to addressing unmet medical needs in infectious diseases, Scynexis is well-positioned to enhance its market presence within the evolving landscape of antifungal treatments.